Data Brokers and the Sale of Americans’ Mental Health Data

Imatge
Adjunts
Adjunt Mida
Report 397.48 KB
Àmbits Temàtics

The Exchange of Our Most Sensi­tive Data and What It Means for Perso­nal Privacy

This report inclu­des findings from a two-month-long study of data brokers and data on U.S. indi­vi­du­als’ mental health condi­ti­ons. The report aims to make more trans­pa­rent the data broker industry and its proces­ses for selling and exchan­ging mental health data about depres­sed and anxi­ous indi­vi­du­als. The rese­arch is criti­cal as more depres­sed and anxi­ous indi­vi­du­als utilize perso­nal devi­ces and soft­ware-based health-trac­king appli­ca­ti­ons (many of which are not protec­ted by the Health Insu­rance Porta­bi­lity and Accoun­ta­bi­lity Act), often unkno­wingly putting their sensi­tive mental health data at risk. This report finds that the industry appe­ars to lack a set of best prac­ti­ces for hand­ling indi­vi­du­als’ mental health data, parti­cu­larly in the areas of privacy and buyer vetting. It finds that there are data brokers which adver­tise and are willing and able to sell data concer­ning Ameri­cans’ highly sensi­tive mental health infor­ma­tion. It conclu­des by arguing that the largely unre­gu­la­ted and black-box nature of the data broker industry, its buying and selling of sensi­tive mental health data, and the lack of clear consu­mer privacy protec­ti­ons in the U.S. neces­si­tate a compre­hen­sive fede­ral privacy law or, at the very least, an expan­sion of HIPA­A’s privacy protec­ti­ons along­side bans on the sale of mental health data on the open market.

 

Key Findings:
  • Some data brokers are marke­ting highly sensi­tive data on indi­vi­du­als’ mental health condi­ti­ons on the open market, with seemingly mini­mal vetting of custo­mers and seemingly few controls on the use of purcha­sed data.
  • 26 of the 37 contac­ted data brokers respon­ded to inqui­ries about mental health data, and 11 firms were ulti­ma­tely willing and able to sell the reques­ted mental health data.
  • Whet­her this data will be deiden­ti­fied or aggre­ga­ted is also often unclear, and many of the studied data brokers at least seem to imply that they have the capa­bi­li­ties to provide iden­ti­fi­a­ble data.
  • The 10 most enga­ged data brokers asked about the purpose of the purchase and the inten­ded use cases for the data; howe­ver, after recei­ving that infor­ma­tion (verbally or in writing) from the author, those compa­nies did not appear to have addi­ti­o­nal controls for client manage­ment, and there was no indi­ca­tion in emails and phone calls that they had conduc­ted sepa­rate back­ground checks to corro­bo­rate the author’s (non-decep­tive) state­ments.
  • The 10 most enga­ged brokers adver­ti­sed highly sensi­tive mental health data on Ameri­cans inclu­ding data on those with depres­sion, atten­tion disor­der, insom­nia, anxi­ety, ADHD, and bipo­lar disor­der as well as data on ethni­city, age, gender, zip code, reli­gion, chil­dren in the home, mari­tal status, net worth, credit score, date of birth, and single parent status.
  • Pricing for mental health infor­ma­tion varied: one data broker char­ged $275 for 5,000 aggre­ga­ted counts of Ameri­cans’ mental health records, while other firms char­ged upwards of $75,000 or $100,000 a year for subs­crip­tion/licen­sing access to data that inclu­ded infor­ma­tion on indi­vi­du­als’ mental health condi­ti­ons.
  • One company that the author was in contact with depic­ted their firm as an adver­ti­sing tech firm. The sales repre­sen­ta­tive offe­red to ask their mana­ger about coor­di­na­ting a data deal on infor­ma­tion from orga­ni­za­ti­ons they adver­tise for on behalf of the author.
  • Data broker 1 empha­si­zed that the reques­ted data on indi­vi­du­als’ mental health condi­ti­ons was “extre­mely restric­ted” and that their team would need more infor­ma­tion on inten­ded use cases—yet conti­nued to send a sample of aggre­ga­ted, deiden­ti­fied data counts.
  • After data broker 1 confir­med that the author was not part of a marke­ting entity, the sales repre­sen­ta­tive said that as long as the author did not contact the indi­vi­du­als in the data­set, the author could use the data freely.
  • Data broker 2 implied they may have fully iden­ti­fied pati­ent data, but said they were unable to share this indi­vi­dual-level data due to HIPAA compli­ance concerns. Instead, the sales repre­sen­ta­tive offe­red to aggre­gate the data of inter­est in a deiden­ti­fied form.
  • Data broker 4 was the most willing to sell data on depres­sed and anxi­ous indi­vi­du­als at the author’s budget price of $2,500 and stated no appa­rent, restric­tive data-use limi­ta­ti­ons post-purchase.
  • Data broker 4 adver­ti­sed highly sensi­tive mental health data to the author, inclu­ding names and postal addres­ses of indi­vi­du­als with depres­sion, bipo­lar disor­der, anxi­ety issues, panic disor­der, cancer, PTSD, OCD, and perso­na­lity disor­der, as well as indi­vi­du­als who have had stro­kes and data on those people’s races and ethni­ci­ties.
  • Two data brokers, data broker 6 and data broker 9, menti­o­ned nondis­clo­sure agre­e­ments (NDAs) in their commu­ni­ca­ti­ons, and data broker 9 indi­ca­ted that signing an NDA was a prere­qui­site for obtai­ning access to infor­ma­tion on the data it sells.
  • Data broker 8 often made unso­li­ci­ted calls to the author’s perso­nal cell. If the author was delayed in respon­ding to an email from data broker 8, the frequency of calls seemed to incre­ase.
  • Some brokers impo­sed data use limi­ta­ti­ons on the possi­ble sale of people’s mental health infor­ma­tion, ranging from “single-use” (which usually pertains to mailing purpo­ses) to “multi-use” (which means the data­set is avai­la­ble for one year after purchase) based on the firm and the product purcha­sed.
  • Based on an evalu­a­tion of privacy poli­cies, data brokers seem collec­ti­vely less willing to provide access and disclo­sure to their custo­mers and users about the collec­tion or correc­tion of perso­nal data.
 

 

 

By: Joanne Kim